314 related articles for article (PubMed ID: 34204146)
1. Chemokines in Severe Cutaneous Adverse Reactions (SCARs).
Miyagawa F; Asada H
Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34204146
[TBL] [Abstract][Full Text] [Related]
2. Differential expression profile of Th1/Th2-associated chemokines characterizes Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS) as distinct entities.
Miyagawa F; Hasegawa A; Imoto K; Ogawa K; Kobayashi N; Ito K; Fujita H; Aihara M; Watanabe H; Sueki H; Tohyama M; Asada H
Eur J Dermatol; 2015; 25(1):87-9. PubMed ID: 25547780
[No Abstract] [Full Text] [Related]
3. Cicatrizing Conjunctivitis in a Patient Diagnosed With Drug Reaction With Eosinophilia and Systemic Symptoms/Drug-Induced Hypersensitivity Syndrome but With Features of Stevens-Johnson Syndrome.
Bohm KJ; Ciralsky JB; Harp JL; Bajaj S; Sippel KC
Cornea; 2016 Jun; 35(6):888-91. PubMed ID: 27078005
[TBL] [Abstract][Full Text] [Related]
4. The interferon-γ-induced protein 10/CXCR3 axis is associated with human herpesvirus-6 reactivation and the development of sequelae in drug reaction with eosinophilia and systemic symptoms.
Yang CW; Cho YT; Hsieh YC; Hsu SH; Chen KL; Chu CY
Br J Dermatol; 2020 Nov; 183(5):909-919. PubMed ID: 32037509
[TBL] [Abstract][Full Text] [Related]
5. Identification of thymus and activation-regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS).
Ogawa K; Morito H; Hasegawa A; Daikoku N; Miyagawa F; Okazaki A; Fukumoto T; Kobayashi N; Kasai T; Watanabe H; Sueki H; Iijima M; Tohyama M; Hashimoto K; Asada H
J Dermatol Sci; 2013 Jan; 69(1):38-43. PubMed ID: 23141052
[TBL] [Abstract][Full Text] [Related]
6. Serum Soluble OX40 as a Diagnostic and Prognostic Biomarker for Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms.
Mitsui Y; Shinkuma S; Nakamura-Nishimura Y; Ommori R; Ogawa K; Miyagawa F; Mori Y; Tohyama M; Asada H
J Allergy Clin Immunol Pract; 2022 Feb; 10(2):558-565.e4. PubMed ID: 34757063
[TBL] [Abstract][Full Text] [Related]
7. Stevens-Johnson syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clinical and laboratory features with drug-induced hypersensitivity syndrome, despite differences in cutaneous presentations.
Teraki Y; Shibuya M; Izaki S
Clin Exp Dermatol; 2010 Oct; 35(7):723-8. PubMed ID: 19874350
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum osteopontin levels in patients with severe cutaneous adverse drug reactions.
Suzuki M; Koshikawa S; Watanabe H; Inomata N; Yamaguchi Y; Aihara M; Sueki H
J Dermatol; 2023 Apr; 50(4):536-540. PubMed ID: 36540013
[TBL] [Abstract][Full Text] [Related]
9. Monitoring the acute response in severe hypersensitivity reactions to drugs.
Shiohara T; Mizukawa Y; Aoyama Y
Curr Opin Allergy Clin Immunol; 2015 Aug; 15(4):294-9. PubMed ID: 26110678
[TBL] [Abstract][Full Text] [Related]
10. Current Perspective Regarding the Immunopathogenesis of Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms (DIHS/DRESS).
Miyagawa F; Asada H
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670052
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal analysis of antibody profiles against plakins in severe drug eruptions: emphasis on correlation with tissue damage in drug-induced hypersensitivity syndrome and drug reaction with eosinophilia and systemic symptoms.
Takehara A; Aoyama Y; Kurosawa M; Shirafuji Y; Umemura H; Kamiya K; Ushigome Y; Kano Y; Shiohara T; Iwatsuki K
Br J Dermatol; 2016 Nov; 175(5):944-952. PubMed ID: 27087170
[TBL] [Abstract][Full Text] [Related]
12. Undiagnosed and Rare Diseases in Critical Care: Severe Mucocutaneous Medication Reactions.
Shields BE; Wanat KA; Chiu YE
Crit Care Clin; 2022 Apr; 38(2):243-269. PubMed ID: 35369946
[TBL] [Abstract][Full Text] [Related]
13. The dynamics of herpesvirus reactivations during and after severe drug eruptions: their relation to the clinical phenotype and therapeutic outcome.
Ishida T; Kano Y; Mizukawa Y; Shiohara T
Allergy; 2014 Jun; 69(6):798-805. PubMed ID: 24749495
[TBL] [Abstract][Full Text] [Related]
14. Immunohistopathological Findings of Severe Cutaneous Adverse Drug Reactions.
Orime M
J Immunol Res; 2017; 2017():6928363. PubMed ID: 29226159
[TBL] [Abstract][Full Text] [Related]
15. HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review.
Cheng CY; Su SC; Chen CH; Chen WL; Deng ST; Chung WH
J Immunol Res; 2014; 2014():565320. PubMed ID: 24901010
[TBL] [Abstract][Full Text] [Related]
16. Recognition and Management of Severe Cutaneous Adverse Drug Reactions (Including Drug Reaction with Eosinophilia and Systemic Symptoms, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis).
Owen CE; Jones JM
Med Clin North Am; 2021 Jul; 105(4):577-597. PubMed ID: 34059239
[TBL] [Abstract][Full Text] [Related]
17. Severe Cutaneous Adverse Drug Reactions in Pediatric Patients: A Multicenter Study.
Dibek Misirlioglu E; Guvenir H; Bahceci S; Haktanir Abul M; Can D; Usta Guc BE; Erkocoğlu M; Toyran M; Nacaroglu HT; Civelek E; Buyuktiryaki B; Ginis T; Orhan F; Kocabas CN
J Allergy Clin Immunol Pract; 2017; 5(3):757-763. PubMed ID: 28351788
[TBL] [Abstract][Full Text] [Related]
18. Severe cutaneous adverse reactions: A 5-year retrospective study at Hospital Melaka, Malaysia, from December 2014 to February 2020.
Tee CT; Abdullah NH; Kristummoonthy P; Lee CS
Med J Malaysia; 2022 Jul; 77(4):409-414. PubMed ID: 35902928
[TBL] [Abstract][Full Text] [Related]
19. Association of HLA genotypes with phenytoin induced severe cutaneous adverse drug reactions in Thai children.
Manuyakorn W; Likkasittipan P; Wattanapokayakit S; Suvichapanich S; Inunchot W; Wichukchinda N; Khongkhatithuml C; Thampratankul L; Kamchaisatian W; Benjaponpitak S; Mahasirimongkol S
Epilepsy Res; 2020 May; 162():106321. PubMed ID: 32272329
[TBL] [Abstract][Full Text] [Related]
20. Differential cytokine profiles produced by anti-epileptic drug re-exposure of peripheral blood mononuclear cells derived from severe anti-epileptic drug patients and non-allergic controls.
Srinoulprasert Y; Kumkamthornkul P; Tuchinda P; Wongwiangjunt S; Sathornsumetee S; Jongjaroenprasert K; Kulthanan K
Cytokine; 2022 Sep; 157():155951. PubMed ID: 35772364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
